ABSTRAL® is the novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, a well-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for chronic pain.

Marketed by Kyowa Kirin in

  • Japan

Marketed by Kyowa Kirin International in